TrialCurveSUNMO (Japanese subgroup): reconstructed Kaplan–Meier curves
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Int J Clin Oncol. 2026 Jun 15;31(8):1547–56. doi: 10.1007/s10147-026-03042-x |
|---|---|
| DOI | 10.1007/s10147-026-03042-x |
| Registry | NCT05171647 |
| Phase | Phase 3 |
| Conditions | Non-Hodgkin Lymphoma |
| Interventions | Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin |
| Sponsor | Hoffmann-La Roche |
| Enrolment | 208 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival (centrally assessed, primary analysis) — ITT population
From figure panel A · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Mosun-Pola 16.2 months; R-GemOx 3.9 months. Survival at 6 months: Mosun-Pola 78%; R-GemOx 43%. Hazard ratio Mosun-Pola vs R-GemOx 0.72 (95% CI 0.18–2.98).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Mosun-Pola | 9 | 6 | 16.2 |
| R-GemOx | 7 | 3 | 3.9 |
- Mosun-Pola vs R-GemOx: reconstructed HR 0.72 (95% CI 0.18–2.98)
Landmark survival (reconstructed)
| Time | Mosun-Pola | R-GemOx |
|---|---|---|
| 6 mo | 77.8% | 42.9% |
| 12 mo | 64.8% | 42.9% |
| 18 mo | 25.9% | 42.9% |
Overall survival (interim analysis) — ITT population
From figure panel B · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Mosun-Pola not reached; R-GemOx not reached. Survival at 12 months: Mosun-Pola 78%; R-GemOx 67%. Hazard ratio R-GemOx vs Mosun-Pola 1.45 (95% CI 0.20–10.34).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Mosun-Pola | 9 | 2 | not reached |
| R-GemOx | 7 | 2 | not reached |
- R-GemOx vs Mosun-Pola: reconstructed HR 1.45 (95% CI 0.20–10.34)
Landmark survival (reconstructed)
| Time | Mosun-Pola | R-GemOx |
|---|---|---|
| 6 mo | 88.9% | 83.3% |
| 12 mo | 77.8% | 66.7% |
| 18 mo | 77.8% | 66.7% |
| 24 mo | 77.8% | 66.7% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/sunmo-japanese-subgroup-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/sunmo-japanese-subgroup-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Int J Clin Oncol. 2026 Jun 15;31(8):1547–56. doi: 10.1007/s10147-026-03042-x doi:10.1007/s10147-026-03042-x. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/sunmo-japanese-subgroup
Report a problem with these data
Related trials
- ECHELON-2 (5-year update): Overall survival; Progression-free survival per investigator
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- PROLONG (final analysis): Overall survival; PFS after next-line treatment (randomization to second progression or de
- ENRICH: Overall survival; Progression-free survival
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials